Mga Batayang Estadistika
| LEI | 5299004QMIHMZUUNYY44 |
| CIK | 1016169 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Antares Pharma Inc
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 10, 2023 |
ATRS / Antares Pharma Inc / Versor Investments LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 3, 2022 |
15-12B 1 d368239d1512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-32302 Antares Pharma, Inc. (Exact name |
|
| May 31, 2022 |
X0101 EFFECT 33 LIVE 2022-05-31 0001193125-22-158575 POS AM 0001016169 ANTARES PHARMA, INC. 333-144748 |
|
| May 24, 2022 |
Second Amended and Restated By-Laws of the Surviving Corporation, dated May 24, 2022. Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ANTARES PHARMA, INC. (a Delaware corporation) ARTICLE I Stockholders SECTION 1. Annual Meetings. The annual meeting of the stockholders of Antares Pharma, Inc. (the ?Corporation?) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held each year at such date and time, within |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 6) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 036642 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 S-8 POS 1 d319953ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-20389 Registration No. 333-40483 Registration No. 333-64480 Registration No. 333-111177 Registration No. 333-117250 Registration No. 333-134258 Registration No. 333-152472 Registration No. 333-167457 Registration No. 333-180832 Registration No. 333-189172 Registration No. 3 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Antares Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other Jurisdiction of Incorporation) (Commission File |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
SC TO-T/A 1 d273015dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Pa |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 POS AM 1 d258396dposam.htm POS AM As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. 333-49249 Registration No. 333-61950 Registration No. 333-96739 Registration No. 333-103958 Registration No. 333-133218 Registration No. 333-142323 Registration No. 333-144748 Registration No. 333-158630 Registration No. 333-167975 Registration No. 333-196051 Registration No. 333 |
|
| May 24, 2022 |
Amended and Restated Certificate of Incorporation of the Surviving Corporation, dated May 24, 2022. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANTARES PHARMA, INC. FIRST: The name of the corporation is: Antares Pharma, Inc. (the ?Corporation?). SECOND: The address of the registered office of the Corporation in the State of Delaware is: The Corporation Trust Company, 1209 Orange Street, Wilmington, Delaware, 19801, New Castle County. The name of its registered agent for serv |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 24, 2022 |
As filed with the Securities and Exchange Commission on May 24, 2022 As filed with the Securities and Exchange Commission on May 24, 2022 Registration No. |
|
| May 13, 2022 |
SC 14D9/A 1 ny20003961x4sc14d9a.htm FORM SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0 |
|
| May 12, 2022 |
SC 14D9/A 1 ny20003961x3sc14d9a.htm FORM SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0 |
|
| May 12, 2022 |
SC TO-T/A 1 d264365dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Pa |
|
| May 12, 2022 |
Hart-Scott-Rodino Waiting Period Expires for Halozyme’s Acquisition of Antares Pharma Exhibit (a)(5)(K) Hart-Scott-Rodino Waiting Period Expires for Halozyme?s Acquisition of Antares Pharma SAN DIEGO, May 12, 2022 ? Halozyme Therapeutics, Inc. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-32302 ANTARES P |
|
| May 10, 2022 |
SC 14D9/A 1 ny20003961x2sc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 p |
|
| May 6, 2022 |
ATRS / Antares Pharma Inc / Versor Investments LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 5, 2022 |
SC 14D9/A 1 brhc10037252sc14dpa.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 p |
|
| May 2, 2022 |
SC TO-T/A 1 d352831dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Pa |
|
| May 2, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Intersect ENT, Inc., and further agree that this Joint Filing Agreement be included as an |
|
| May 2, 2022 |
SC 14D9/A 1 ny20002681x4sc14d9a.htm SC14D9A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per |
|
| May 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ANTARES PHARMA, INC. |
|
| May 2, 2022 |
ATRS / Antares Pharma Inc / Magnetar Financial LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Antares Pharma, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 036642106 (CUSIP Number of Class of Securities) Alec N. Litowitz Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Name, Add |
|
| May 2, 2022 |
BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 Exhibit (b)(2) STRICTLY CONFIDENTIAL Execution Version BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 WELLS FARGO BANK, NATIONAL ASSOCIATION WELLS FARGO SECURITIES, LLC 550 South Tyron Street Charlotte, NC 28202 CONFIDENTIAL April 28, 2022 PROJECT ATLAS $375.0 million Term Loan Facility Amended and Restated Commitment Letter Halozyme Therapeutics, Inc. 11388 S |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-32302 |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company (Issuer)) ATLAS MERGER SUB, INC. HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 0366 |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 ? (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. ? (Name of Subject Company) Antares Pharma, Inc. ? (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 036642106 (CUSIP N |
|
| April 26, 2022 |
Exhibit (d)(2) CONFIDENTIALITY AGREEMENT This agreement (this ?Agreement?), dated February 18, 2022 (the ?Effective Date?), shall serve to set forth the terms and conditions between Antares Pharma, Inc. |
|
| April 26, 2022 |
HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA Exhibit (a)(5)(J) HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA SAN DIEGO, April 26, 2022 ? Halozyme Therapeutics, Inc. |
|
| April 26, 2022 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(A) Offer To Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 26, 2022 |
BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 Exhibit (b)(1) BANK OF AMERICA, N.A. BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 CONFIDENTIAL April 12, 2022 PROJECT ATLAS $75.0 million Revolving Credit Facility $375.0 million Term Loan Facility Commitment Letter Halozyme Therapeutics, Inc. 11388 Sorrento Valley Road San Diego, CA 92121 Email: [email protected] Phone: (858) 794-8889 Ladies and Gentlemen: Halozyme Therapeutics |
|
| April 26, 2022 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ANTARES PHARMA, INC. |
|
| April 26, 2022 |
[Remainder of this page intentionally left blank.] Exhibit (d)(3) STRICTLY PRIVATE AND CONFIDENTIAL March 17, 2022 Robert F. Apple President and Chief Executive Officer Antares Pharma, Inc. 100 Princeton South, Suite 300 Ewing, New Jersey 08628 Re: Exclusivity Agreement Dear Bob: Reference is made to our discussions regarding a possible negotiated acquisition (the ?Proposed Transaction?) of all of the issued and outstanding shares of common stock |
|
| April 14, 2022 |
SC TO-C 1 d339898dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANTARES PHARMA, INC. (Name of Subject Company) ATLAS MERGER SUB, INC. a wholly owned subsidiary of HALOZYME THERAPEUTICS, INC. (Names of Filing Persons — Offerors) Common Stock, Par V |
|
| April 14, 2022 |
Exhibit (a)(5)(G) REFINITIV STREETEVENTS EDITED TRANSCRIPT HALO.OQ - Halozyme Therapeutics Inc to Acquire Antares Pharma Inc to Create a Specialty Product and Drug Delivery Leader Call EVENT DATE/TIME: APRIL 13, 2022 / 12:00PM GMT REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us ?2022 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 Antares Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| April 13, 2022 |
SC TO-C 1 d259127dsctoc.htm SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 12, 2022 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488 |
|
| April 13, 2022 |
Creating a Specialty Product and Drug Delivery Leader with Antares Exhibit (a)(5)(D) Creating a Specialty Product and Drug Delivery Leader with Antares April 13, 2022 Dear [INSERT]: Today, we announced that Halozyme is acquiring Antares Pharma, Inc. |
|
| April 13, 2022 |
Exhibit (a)(5)(C) Employee FAQ 1. What was announced? ? We recently announced that Halozyme is acquiring Antares to create an industry-leading, drug delivery and specialty product company. ? Both companies possess highly complementary science, products and capabilities, and, together, we will be able to offer even more opportunities for our team and benefits for patients. 2. Who is Antares? ? Anta |
|
| April 13, 2022 |
Exhibit 99.2 Employee Note from Bob Apple Dear Colleagues, I have some very exciting and important news to share with you today. Antares has entered into an agreement to be acquired by Halozyme Therapeutics, Inc (NASDAQ: HALO), for $5.60 per share in cash, which values Antares at approximately $1 billion. Halozyme is a San Diego-based biopharmaceutical company that uses innovative and disruptive s |
|
| April 13, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among HALOZYME THERAPEUTICS, INC., ATLAS MERGER SUB, INC. and ANTARES PHARMA, INC. Dated as of April 12, 2022 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 4 ARTICLE II MERGER TRANSACTION 4 Section 2.1 Merger of Purchaser into the Company 4 Section 2.2 Effect of the Merger 4 Section 2.3 Cl |
|
| April 13, 2022 |
Exhibit 99.5 |
|
| April 13, 2022 |
Amendment to the Amended and Restated By-laws of Antares Pharma, Inc. Article VII Exhibit 3.1 Amendment to the Amended and Restated By-laws of Antares Pharma, Inc. Article VII SECTION 1.?Forum for Adjudication of Certain Disputes. Unless the Corporation consents in writing to the selection of an alternative forum (an ?Alternative Forum Consent?), the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brou |
|
| April 13, 2022 |
Exhibit 99.1 Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix w |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Antares Pharma, Inc. (Name of Subject Company) Antares Pharma, Inc. (Name of Persons Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) 036642106 (CUSIP Number |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2022 Antares Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other Jurisdiction of Incorporation) (Commission Fil |
|
| April 13, 2022 |
Exhibit 99.1 |
|
| April 13, 2022 |
Exhibit 99.1 Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix w |
|
| April 13, 2022 |
Exhibit (a)(5)(F) Twitter Post LinkedIn Post Forward Looking Statements This communication contains ?forward-looking statements?. |
|
| April 13, 2022 |
Exhibit (a)(5)(A) To: Antares Employees From: Helen Torley Date: April 13, 2022 Subject: Welcome to the Halozyme Team Dear Antares Team, What an exciting day for both of our companies. |
|
| April 13, 2022 |
Exhibit (a)(5)(E) Halozyme to Acquire Antares to Create a Specialty Product and Drug Delivery Leader Expected to be Immediately Accretive to Revenue and Earnings Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Three Commercial Products Targeting Key Audiences Immediate Revenue and Non-GAAP Earnings Ac |
|
| April 13, 2022 |
Exhibit 99.3 Partner Note Subject: Antares Pharma to be Acquired by Halozyme Therapeutics Hi [NAME], This morning, Antares Pharma announced that it has entered an agreement to be acquired by Halozyme Therapeutics (NASDAQ: HALO), a San Diego-based biopharmaceutical company that uses innovative and disruptive solutions to improve patient experiences and outcomes for emerging and established therapie |
|
| April 13, 2022 |
Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among HALOZYME THERAPEUTICS, INC., ATLAS MERGER SUB, INC. and ANTARES PHARMA, INC. Dated as of April 12, 2022 TABLE OF CONTENTS Page ARTICLE I THE OFFER 2 Section 1.1 The Offer 2 Section 1.2 Company Actions 4 ARTICLE II MERGER TRANSACTION 4 Section 2.1 Merger of Purchaser into the Company 4 Section 2.2 Effect of the Merger 4 Section 2.3 Cl |
|
| April 13, 2022 |
Amendment to the Company’s Amended and Restated By-laws, dated April 12, 2022 (filed as Exhibit Exhibit 3.1 Amendment to the Amended and Restated By-laws of Antares Pharma, Inc. Article VII SECTION 1.?Forum for Adjudication of Certain Disputes. Unless the Corporation consents in writing to the selection of an alternative forum (an ?Alternative Forum Consent?), the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brou |
|
| April 13, 2022 |
Exhibit (a)(5)(B) To: Halozyme Employees From: Helen Torley Date: April 13, 2022 Subject: Creating a Specialty Product and Drug Delivery Leader with Antares Dear Colleagues, I am writing to you all today to share some important news. |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 ANTARES PHARMA, INC. (Name of Subject Company) ATLAS MERGER SUB, INC. a wholly owned subsidiary of HALOZYME THERAPEUTICS, INC. (Names of Filing Persons ? Offerors) Common Stock, Par Value $0.01 Per Share (Title of Class |
|
| April 13, 2022 |
Exhibit 99.4 To: Antares Employees From: Helen Torley Date: April 13, 2022 Subject: Welcome to the Halozyme Team Dear Antares Team, What an exciting day for both of our companies. On behalf of everyone at Halozyme, we couldn?t be more excited for all that is ahead. For those of you who may not be familiar with us, we are a biopharmaceutical company dedicated to bringing disruptive solutions to sig |
|
| March 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| March 7, 2022 |
NASDAQ: ATRS | March 2022 Investor Presentation Exhibit 99.1 2March 2022 Safe Harbor Statement & Non-GAAP Metrics This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially |
|
| March 3, 2022 |
Exhibit 10.14 Execution Version ANTARES PHARMA, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into on this 22nd day of April, 2021, effective as of the 26th day of April 2021 (the ?Effective Date?) by and between Antares Pharma, Inc., a Delaware corporation (the ?Company?), and Dr. Peter C. Richardson. (the ?Executive?). WITNESSETH: WHEREAS, the Company |
|
| March 3, 2022 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT by and between OTTER PHARMACEUTICALS, LLC, ANTARES PHARMA, INC., and ASSERTIO HOLDINGS, INC. Dated as of December 15, 2021 TABLE OF CONTENTS Page ARTIC |
|
| March 3, 2022 |
Exhibit 99.1 ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL AND OPERATING RESULTS Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, NJ, March 3, 2022 ? Antares Pharma, I |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 001-32302 ANTARES PHARMA, INC. |
|
| February 14, 2022 |
ATRS / Antares Pharma Inc / Rubric Capital Management LP - SC 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Antares Pharma, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 12, 2022 |
1January 2022 NASDAQ: ATRS | January 2022 Investor Presentation EX 99.1 2January 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from th |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 11, 2022 |
1January 2022 NASDAQ: ATRS | January 2022 Investor Presentation EX 99.1 2January 2022 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from th |
|
| January 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| December 16, 2021 |
ANTARES PHARMA ANNOUNCES DIVESTITURE OF OTREXUP® Exhibit 99.1 ANTARES PHARMA ANNOUNCES DIVESTITURE OF OTREXUP? EWING, NJ, December 15, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (the ?Company?), a specialty pharmaceutical company, today announced the divestiture of OTREXUP? (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash considera |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32302 ANTARE |
|
| November 4, 2021 |
Exhibit 99.1 ANTARES PHARMA REPORTS THIRD QUARTER 2021 FINANCIAL AND OPERATING RESULTS Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, NJ, November 4, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (the ?Company?), a specialty pharmaceutical company, today reported financial and operating results for the third q |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission F |
|
| November 2, 2021 |
argo Bank, National Association, and the lenders from time to time party thereto EXHIBIT 10.1 EXECUTION VERSION i $40,000,000 CREDIT AGREEMENT dated as of November 1, 2021, by and among ANTARES PHARMA, INC., as Borrower, the Lenders referred to herein, as Lenders, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent, Swingline Lender and Issuing Lender WELLS FARGO SECURITIES, LLC, as Sole Lead Arranger and Sole Bookrunner TABLE OF CONTENTS Page -i- ARTICLE I DEF |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2021 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission F |
|
| October 28, 2021 |
ANTARES PHARMA ANNOUNCES APPOINTMENT OF CARMEN VOLKART TO ITS BOARD OF DIRECTORS Exhibit 99.1 ANTARES PHARMA ANNOUNCES APPOINTMENT OF CARMEN VOLKART TO ITS BOARD OF DIRECTORS EWING, NJ, October 28, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (the ?Company?), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device execu |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| October 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 001-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| October 18, 2021 |
Exhibit 99.1 ANTARES PHARMA ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH LIPOCINE FOR TLANDO? IN U.S. Expands Proprietary Portfolio and Complements Testosterone Offering to Physicians and Patients EWING, NJ, October 18, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (the ?Company?), a specialty pharmaceutical company, today announced that it entered into an exclusive license agreement with Lipocine In |
|
| August 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 18, 2021 |
1August 2021 NASDAQ: ATRS | August 2021 Investor Presentation EX99.1 2August 2021 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those |
|
| August 5, 2021 |
EX99.1 ANTARES PHARMA REPORTS SECOND QUARTER 2021 FINANCIAL AND OPERATING RESULTS Increased Revenue 39% Year-Over-Year to $45.0 Million Doubled Net Income to $4.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, NJ, August 5, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (?the Company?), a specialty pharmaceutical company, today reported financial and operating results for the second |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware |
|
| June 24, 2021 |
Exhibit 4.1 ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN (As Amended and Restated) The Antares Pharma, Inc. Equity Compensation Plan (the ?Plan?) (formerly the Antares Pharma, Inc. 2008 Equity Compensation Plan) was established effective as of May 14, 2008 and was most recently amended and restated effective as of June 13, 2019. This amendment and restatement will be effective June 10, 2021, subj |
|
| June 24, 2021 |
As filed with the Securities and Exchange Commission on June 24, 2021 As filed with the Securities and Exchange Commission on June 24, 2021 Registration No. |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 1, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 1, 2021 |
NASDAQ: ATRS | June 2021 Investor Presentation EX-99.1 NASDAQ: ATRS | June 2021 Investor Presentation EX-99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware |
|
| May 6, 2021 |
EX 99.1 ANTARES PHARMA REPORTS FIRST QUARTER 2021 FINANCIAL AND OPERATING RESULTS Increased Revenue 27% Year-Over-Year to $42.1 Million Increased Net Income to $3.8 Million, or $0.02 Per Basic and Diluted Earnings Per Share EWING, NJ, May 6, 2021 ? Antares Pharma, Inc. (NASDAQ: ATRS) (?the Company?), a specialty pharmaceutical company, today reported financial and operating results for the quarter |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary proxy statement. [ ] Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)). [X] Definitive |
|
| April 27, 2021 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] ? ? Preliminary proxy statement. [ ] ? ? Confidential, for use of the Commission only (as permitted by Rule 14 |
|
| March 5, 2021 |
NASDAQ: ATRS | March 2021 Investor Presentation EX99.1 NASDAQ: ATRS | March 2021 Investor Presentation EX99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may |
|
| March 5, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 2, 2021 |
EX 99.1 ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2020 FINANCIAL AND OPERATING RESULTS Full-Year 2020 Revenue Increases 21% Year-Over-Year to $149.6 Million Full-Year 2020 Net Income Before Income Taxes of $9.9 Million, or $0.06 per Share Full-Year 2020 Net Income of $56.2 Million, including a Net Tax Benefit of $46.3 million EWING, NJ, March 2, 2021 – Antares Pharma, Inc. (NASDAQ: ATRS) |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-32302 ANTARES PHARMA, INC. (Exact name |
|
| January 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 11, 2021 |
EX 99.1 ANTARES PHARMA ANNOUNCES FULL-YEAR 2021 REVENUE GUIDANCE OF $175-200 MILLION Company updates full-year 2020 revenue guidance to $145-150 million EWING, NJ, January 11, 2021 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue to be in a range of $175 to $200 million, which assumes no sign |
|
| January 11, 2021 |
NASDAQ: ATRS | January 2021 Investor Presentation EX 99.2 NASDAQ: ATRS | January 2021 Investor Presentation EX 99.2 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that |
|
| November 12, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K INVESTOR PRESENTATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2020 |
NASDAQ: ATRS | November 2020 Investor Presentation EX 99.1 NASDAQ: ATRS | November 2020 Investor Presentation EX 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that |
|
| November 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 5, 2020 |
EX 99.1 ANTARES PHARMA REPORTS STRONG THIRD QUARTER 2020 FINANCIAL AND OPERATING RESULTS Third Quarter 2020 Revenue Increases 17% Year-Over-Year to $40.0 Million Third Quarter 2020 Net Income of $5.0 Million, or EPS of $0.03 EWING, NJ, November 5, 2020 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today reported financial and operating results for the |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 1-32302 ANTARES PHARMA, INC. A Dela |
|
| October 1, 2020 |
EX 99.1 ANTARES PHARMA ENTERS EXCLUSIVE LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS FOR NOCDURNA® IN U.S. Antares Expands Urology Portfolio and Leverages Commercial Organization EWING, NJ, October 1, 2020 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals (“F |
|
| October 1, 2020 |
Financial Statements and Exhibits - 8-K ITEM 8.01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| September 21, 2020 |
Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is dated as of September 15, 2020 and is entered into by and between (a) ANTARES PHARMA, INC., a Delaware corporation (“Borrower”), (b) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, refer |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 6, 2020 |
EX 99.1 ANTARES PHARMA REPORTS STRONG SECOND QUARTER 2020 OPERATING AND FINANCIAL RESULTS; REINSTATES FULL-YEAR 2020 REVENUE GUIDANCE • Second Quarter 2020 Revenue of $32.4 Million, a 14% Increase Compared to Second Quarter 2019 • Second Quarter 2020 Net Income of $2.2 Million as Compared to Net Loss of $2.2 Million for Second Quarter 2019 • Reinstates Full-Year 2020 Revenue Guidance Range of $135 |
|
| August 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware |
|
| June 16, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 5, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware |
|
| May 5, 2020 |
EX 99.1 ANTARES PHARMA REPORTS FIRST QUARTER 2020 OPERATING AND FINANCIAL RESULTS • First Quarter 2020 Revenue $33.1 Million, a 42% Increase Compared to First Quarter 2019 • Generated $5.6 Million in Cash from Operations during the First Quarter 2020 EWING, NJ, May 5, 2020 – Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today reported operating and financial results for the first quarter en |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat |
|
| April 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 04, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 4, 2020 |
Antares Pharma Investor’s Update March 2020 Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differe |
|
| March 3, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 3, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-32302 ANTARES PHARMA, INC. (Exact name |
|
| March 3, 2020 |
Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES ACT OF 1934 The following description sets forth certain material terms and provisions of our securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. (A) Description of Common Stock Each holder of our common stock is entitled to one vote for each sh |
|
| March 3, 2020 |
Exhibit 99.1 ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 OPERATING AND FINANCIAL RESULTS Record Quarterly Revenue of $37.8 Million – Earnings Per Share of $0.03 Record Annual Revenue of $123.9 Million, a 95% Increase over 2018 Annual Revenue EWING, NJ, March 3, 2020 - Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the fourth quar |
|
| February 14, 2020 |
ATRS / Antares Pharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2020 |
ATRS / Antares Pharma, Inc. / UBS Group AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Antares Pharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| January 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 27, 2020 |
EX 99.1 p ANTARES PHARMA ANNOUNCES FULL-YEAR 2020 NET REVENUE GUIDANCE RANGE OF $135 to $155 MILLION The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance EWING, NJ, January 27, 2020 - Antares Pharma, Inc. (NASDAQ: ATRS) (The Company) today announced 2020 full-year net revenue guidance of $135 to $155 million, which includes a range of potential revenue |
|
| January 13, 2020 |
Antares Pharma Investor’s Update January 2020 EX 99.1 Antares Pharma Investor’s Update January 2020 EX 99.1 This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such difference |
|
| January 13, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 5, 2019 |
EX99.1 ANTARES PHARMA REPORTS THIRD QUARTER 2019 OPERATING AND FINANCIAL RESULTS Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING, NJ, November 5, 2019 - Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the third quarter end |
|
| November 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation (State or Other Jurisdiction of Incorporation) 41-1350192 (I.R.S. Employer Identification No.) 100 Princ |
|
| September 10, 2019 |
Antares Pharma Investors’ Update September 2019 EX 99.1 Antares Pharma Investors’ Update September 2019 EX 99.1 This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differen |
|
| September 10, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 6, 2019 |
EX-99.1 Exhibit 99.1 ANTARES PHARMA REPORTS SECOND QUARTER 2019 OPERATING AND FINANCIAL RESULTS Record Quarterly Revenue of $28.4 MillionDouble Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million EWING, NJ, August 6, 2019 Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the |
|
| August 6, 2019 |
EX 10.8 NON-EMPLOYEE DIRECTOR FORM ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT GRANT AGREEMENT This RESTRICTED STOCK UNIT GRANT AGREEMENT (this “Agreement”), dated as of , (the “Date of Grant”), is delivered by Antares Pharma, Inc. (the “Company”), to (the “Grantee”). RECITALS The Company maintains the Antares Pharma, Inc. Equity Compensation Plan, as amended and restated ( |
|
| August 6, 2019 |
EX 10.7 NON-EMPLOYEE DIRECTOR FORM ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN NONQUALIFIED STOCK OPTION GRANT AGREEMENT This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (this “Agreement”), dated as of , 20 (the “Date of Grant”), is delivered by Antares Pharma, Inc. (the “Company”) to (the “Grantee”). RECITALS The Company maintains the Antares Pharma, Inc. Equity Compensation Plan, as amended and |
|
| August 6, 2019 |
EX 10.4 ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN NONQUALIFIED STOCK OPTION GRANT AGREEMENT This NONQUALIFIED STOCK OPTION GRANT AGREEMENT (this “Agreement”), dated as of , 20 (the “Date of Grant”), is delivered by Antares Pharma, Inc. (the “Company”) to (the “Grantee”). RECITALS A.The Company maintains the Antares Pharma, Inc. Equity Compensation Plan, as amended and restated (the “Plan”), wh |
|
| August 6, 2019 |
EX 10.5 ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN RESTRICTED STOCK UNIT GRANT AGREEMENT This RESTRICTED STOCK UNIT GRANT AGREEMENT (this “Agreement”), dated as of , (the “Date of Grant”), is delivered by Antares Pharma, Inc. (the “Company”), to (the “Grantee”). RECITALS A. The Company maintains the Antares Pharma, Inc. Equity Compensation Plan, as amended and restated (the “Plan”), which provi |
|
| August 6, 2019 |
EX 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (“Third Amendment”) dated May 7, 2019 by and between PRINCETON OFFICE CENTER, LLC, a Delaware limited liability company (successor in interest and title to Princeton South Investors, LLC) with an office at c/o Vision Management, LLC, 200 PrincetonSouth Corporate Center, Suite 130, Ewing, New Jersey 08628 (“Landlord”) and ANTARES PHARMA |
|
| August 6, 2019 |
EX 10.6 ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN PERFORMANCE STOCK UNIT SUMMARY OF GRANT Antares Pharma, Inc., a Delaware corporation (the “Company”), pursuant to its Equity Compensation Plan, as amended and restated (the “Plan”), hereby grants to the individual listed below (the “Grantee”), this performance stock unit award representing the target number of performance stock units set forth |
|
| August 6, 2019 |
ATRS / Antares Pharma, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation (State or Other Jurisdiction of Incorporation) 41-1350192 (I.R.S. Employer Identification No.) 100 Princeton |
|
| July 23, 2019 |
Exhibit 4.1 ANTARES PHARMA, INC. EQUITY COMPENSATION PLAN (As Amended and Restated) The Antares Pharma, Inc. Equity Compensation Plan (the “Plan”) (formerly the Antares Pharma, Inc. 2008 Equity Compensation Plan) was established effective as of May 14, 2008. This amendment and restatement will be effective June 13, 2019, subject to approval by the stockholders of the Company on such date (“Amendme |
|
| July 23, 2019 |
ATRS / Antares Pharma, Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on July 23, 2019 Registration No. |
|
| July 5, 2019 |
EX 10.1 LEASE AGREEMENT BY AND BETWEEN WHITEWATER PROPERTIES I, LLC as Landlord and ANTARES PHARMA, INC. as Tenant 12500 WHITEWATER DRIVE, MINNETONKA, MINNESOTA TABLE OF CONTENTS LEASE AGREEMENT Article 1 – Basic Lease Provisions and Definitions 1.1 Basic Lease Provisions and Definitions 1 1.2 Landlord Address 1 1.3 Tenant Address 1 1.4 Premises 1 1.5 As-Is Building and Premises 2 1.6 Tenant’s Wor |
|
| July 5, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 27, 2019 |
EX 10.1 First AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is dated as of June 26, 2019 and is entered into by and between (a) ANTARES PHARMA, INC., a Delaware corporation (“Borrower”), (b) the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, referred to as “L |
|
| June 27, 2019 |
EX 99.1 NEWS RELEASE ANTARES PHARMA ANNOUNCES AMENDMENT TO EXISTING LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL Amendment Increases Loan By Up To $25 Million in Non-Dilutive Debt Financing EWING, NJ, June 27, 2019 - Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules C |
|
| June 18, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 18, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 18, 2019 |
NASDAQ: ATRS Raymond James Life Sciences & MedTech Conference June 18, 2019 Robert F. |
|
| May 2, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 2, 2019 |
EXHIBIT 99.1 ANTARES PHARMA REPORTS FIRST QUARTER 2019 OPERATING AND FINANCIAL RESULTS Record Quarterly Revenue of $23.3 Million, an 83% Increase Compared to First Quarter 2018 EWING, NJ, May 2, 2019 - Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019. The Company reported revenue of $23.3 million and a net |
|
| May 2, 2019 |
the Registrants Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation IRS Employer Identification No. 41-1350192 100 Princeton South, Suite 300 Ewing, New Jersey 08628 (609) 359- |
|
| April 26, 2019 |
ATRS / Antares Pharma, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Stat |
|
| April 26, 2019 |
ATRS / Antares Pharma, Inc. DEF 14A DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary proxy statement. o Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)). ☒ |
|
| March 12, 2019 |
Exhibit 10.9 INDEMNIFICATION AGREEMENT This Indemnification Agreement, dated as of [], is made by and between Antares Pharma, Inc., a Delaware corporation (the “Company” or “Antares”), and [] (the “Indemnitee”) an agent (as hereinafter defined) of the Company. R E C I T A L S A. The Company recognizes that competent and experienced persons are sometimes reluctant to serve as directors or officers |
|
| March 12, 2019 |
the Registrants Annual Report on Form 10-K for the fiscal year ended December 31, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-32302 ANTARES PHARMA, INC. (Exact name |
|
| March 5, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 5, 2019 |
NASDAQ: ATRS Raymond James & Associates 40th Annual Institutional Investors Conference March 5, 2019 Robert F. |
|
| March 4, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 4, 2019 |
EXHIBIT 99.1 NEWS RELEASE ANTARES PHARMA APPOINTS DR. KAREN SMITH TO BOARD OF DIRECTORS AND ANNOUNCES RETIREMENT OF DR. JACQUES GONELLA EWING, NJ, March 4, 2019 - Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat being vacated by the retirement of Dr. Jacques Gonella. Dr. Smith has over 20 years of biopharma |
|
| February 28, 2019 |
EX 99.1 ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2018 OPERATING AND FINANCIAL RESULTS Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, NJ, February 28, 2019 - Antares Pharma, Inc. (NASDAQ: ATRS) today reported unaudited consolidated financial results and operational highlights for the f |
|
| February 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| February 14, 2019 |
ATRS / Antares Pharma, Inc. / UBS Group AG - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Antares Pharma Inc (Name of Issuer) Common Stock (Title of Class of Securities) 036642106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2019 |
ATRS / Antares Pharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 7, 2019 |
NASDAQ: ATRS January 2019 Investor Presentation EX 99.1 NASDAQ: ATRS January 2019 Investor Presentation EX 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that ma |
|
| January 7, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| December 13, 2018 |
ANTARES PHARMA ANNOUNCES THE APPOINTMENT OF PETER S. GREENLEAF TO COMPANY’S BOARD OF DIRECTORS EXHIBIT 99.1 ANTARES PHARMA ANNOUNCES THE APPOINTMENT OF PETER S. GREENLEAF TO COMPANY’S BOARD OF DIRECTORS EWING, N.J., December 13, 2018 — Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors. Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. |
|
| November 15, 2018 |
EX-99.1 NASDAQ: ATRS Jefferies 2018 Global Healthcare Conference November 15, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertai |
|
| November 15, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission F |
|
| November 6, 2018 |
Exhibit 99.1 ANTARES PHARMA REPORTS THIRD QUARTER 2018 OPERATING AND FINANCIAL RESULTS The Company Posts Record Quarterly Revenue Of $17.9 Million EWING, NJ, November 6, 2018 - Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today announced operating and financial results for the third quarter ended September 30, 2018. The Company reported revenue of $17.9 million and a net loss per share of $0. |
|
| November 6, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 6, 2018 |
EX-10.1 2 atrs-ex10112.htm EX-10.1 EMPLOYMENT AGREEMENT JAMES P TURSI Exhibit 10.1 ANTARES PHARMA, INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into on this 25th day of July, 2018, effective as of the 6th day of August 2018 (the “Effective Date”) by and between Antares Pharma, Inc., a Delaware corporation (the “Company”), and James P. Tursi, M.D. (the |
|
| November 6, 2018 |
ATRS / Antares Pharma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2018 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation IRS Employer Identification No. 41-1350192 100 Princeton South, Suite 300 Ewing, New Jersey 08628 (609) |
|
| October 2, 2018 |
NASDAQ: ATRS Ladenburg Thalmann 2018 Healthcare Conference October 2, 2018 Robert F. |
|
| October 2, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 6, 2018 |
NASDAQ: ATRS H.C. Wainwright 20th Annual Global Investment Conference September 6, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and unc |
|
| September 6, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 7, 2018 |
Exhibit 99.1 ANTARES PHARMA REPORTS SECOND QUARTER 2018 OPERATING AND FINANCIAL RESULTS Increased Product Revenue, Positive Shift In Revenue Mix Highlights Second Quarter Results EWING, NJ, August 7, 2018 - Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the second quarter ended June 30, 2018. The Company reported revenue of $14.2 million and a |
|
| August 7, 2018 |
ATRS / Antares Pharma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2018 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation IRS Employer Identification No. 41-1350192 100 Princeton South, Suite 300 Ewing, New Jersey 08628 (609) 359-3 |
|
| June 14, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 5, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 5, 2018 |
NASDAQ: ATRS Jefferies 2018 Healthcare Conference June 5, 2018 Robert F. Apple President and Chief Executive Officer Exhibit 99.1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause |
|
| May 9, 2018 |
NASDAQ: ATRS Deutsche Bank Securities 43rd Annual Health Care Conference May 9, 2018 Robert F. |
|
| May 9, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 8, 2018 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 8, 2018 |
Exhibit 99.1 ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS First Quarter Revenue Growth Driven By A Nine Percent Increase In Product Sales EWING, NJ, May 8, 2018 - Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today reported operating and financial results for the first quarter ended March 31, 2018. The Company reported revenue of $12.7 million and a net loss per sh |
|
| May 8, 2018 |
ATRS / Antares Pharma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2018 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation IRS Employer Identification No. 41-1350192 100 Princeton South, Suite 300 Ewing, New Jersey 08628 (609) 359- |
|
| April 27, 2018 |
ATRS / Antares Pharma, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 27, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 27, 2018 |
Exhibit 99.1 ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE The Company Anticipates Second Quarter 2018 Resubmission EWING, NJ, March 27, 2018 - Antares Pharma, Inc. (NASDAQ: ATRS) (the Company) today announced that the official minutes from the Type A meeting with the U.S. Food and Drug Administration (FDA or the Agency) held on February 21, 2018 have been received. The Company had previously |
|
| March 13, 2018 |
Exhibit 99.1 ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS Record Annual Revenue of $54.5 Million EWING, NJ, March 13, 2018 - Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating progress and financial results for the fourth quarter and full year ended December 31, 2017. The Company reported revenue of $14.0 million for the fourth quarter of 2017 |
|
| March 13, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 13, 2018 |
ATRS / Antares Pharma, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-32302 ANTARES PHARMA, INC. (Exact name |
|
| March 5, 2018 |
NASDAQ: ATRS Raymond James & Associates 39th Annual Institutional Investors Conference March 5, 2018 Robert F. |
|
| March 5, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2018 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 16, 2018 |
ATRS / Antares Pharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2018 |
ATRS / Antares Pharma, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2018 |
ATRS / Antares Pharma, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 7, 2017 |
atrs-ex9916.htm Exhibit 99.1 ANTARES PHARMA REPORTS THIRD QUARTER 2017 OPERATING AND FINANCIAL RESULTS Record Quarterly Revenue of $15.1 Million and Net Loss Per Share of $0.03 EWING, NJ, November 7, 2017 - Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the third quarter ended September 30, 2017. The Company reported record revenue of $15.1 million and a net |
|
| November 7, 2017 |
Financial Statements and Exhibits, Results of Operations and Financial Condition atrs-8k20171107.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2017 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation |
|
| November 7, 2017 |
ATRS / Antares Pharma, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2017 Commission File Number 1-32302 ANTARES PHARMA, INC. A Delaware Corporation IRS Employer Identification No. 41-1350192 100 Princeton South, Suite 300 Ewing, New Jersey 08628 (609) |
|
| October 20, 2017 |
Financial Statements and Exhibits, Other Events atrs-8k20171020.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2017 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation |
|
| October 20, 2017 |
ANTARES PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR XYOSTED™ atrs-ex9916.htm Exhibit 99.1 ANTARES PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR XYOSTED? EWING, NJ, October 20, 2017 - Antares Pharma, Inc. (NASDAQ: ATRS) announced that today it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for XYOSTED? (testosterone enanthate) injection. The CRL indicates tha |
|
| October 12, 2017 |
atrs-ex9928.htm Exhibit 99.2 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 209863 DEFICIENCIES PRECLUDE DISCUSSION Antares Pharma, Inc. Attention: Nader Fotouhi, Ph.D. Director, Regulatory Affairs 100 Princeton South, Suite 300 Ewing, NJ 08628 Dear Dr. Fotouhi: Please refer to your New Drug Application (NDA) dated and received December 20, 2016 sub |
|
| October 12, 2017 |
ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE atrs-ex9916.htm Exhibit 99.1 ANTARES PHARMA PROVIDES XYOSTED™ REGULATORY UPDATE EWING, NJ, October 12, 2017 - Antares Pharma, Inc. (NASDAQ: ATRS) today announced that, on October 11, 2017, the Company received a letter from the U.S. Food and Drug Administration (FDA) stating that, as part of their ongoing review of the Company’s New Drug Application (NDA) for XYOSTED™ (testosterone enanthate) inje |
|
| October 12, 2017 |
Financial Statements and Exhibits, Other Events atrs-8k20171011.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2017 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation |
|
| October 10, 2017 |
ANTARES PHARMA ANNOUNCES SALE OF ZOMAJET™ NEEDLE-FREE DELIVERY SYSTEM TO FERRING PHARMACEUTICALS atrs-ex9916.htm Exhibit 99.1 ANTARES PHARMA ANNOUNCES SALE OF ZOMAJET™ NEEDLE-FREE DELIVERY SYSTEM TO FERRING PHARMACEUTICALS EWING, NJ, October 10, 2017 - Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “the Company”) today announced that it has entered into a definitive asset purchase agreement to sell the worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto inje |
|
| October 10, 2017 |
Financial Statements and Exhibits, Other Events atrs-8k20171010.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2017 ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) Delaware 1-32302 41-1350192 (State or other jurisdiction of incorporation |
|
| August 11, 2017 |
ANTARES PHARMA, INC. COMMON STOCK SALES AGREEMENT EX-1.1 Exhibit 1.1 Execution Version ANTARES PHARMA, INC. $30,000,000 COMMON STOCK SALES AGREEMENT August 11, 2017 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Antares Pharma, Inc. (the Company), confirms its agreement (this Agreement) with Cowen and Company, LLC (Cowen), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to |
|
| August 11, 2017 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2017 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 001-32302 41-1350192 (State or Other Jurisdiction of Incorporation) (Comm |
|
| August 11, 2017 |
$30,000,000 Antares Pharma, Inc. Common Stock 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-217808 PROSPECTUS SUPPLEMENT (To Prospectus dated May 18, 2017) $30,000,000 Antares Pharma, Inc. Common Stock Antares Pharma, Inc. (the ?Company?) has entered into a sales agreement with Cowen and Company, LLC (?Cowen?), relating to shares of our common stock, $0.01 par value per share, offered by this prospectus supplem |
|
| August 9, 2017 |
atrs-ex9916.pptx.htm NASDAQ: ATRS August 2017 Exhibit 99.1 Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors th |
